| Prev Close | 182.50 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 99.91 / 187.45 |
Alexion Pharmaceuticals, Inc. (ALXN)
182.50
| Exchange | |
| Div & Yield | N.A. (N.A) |
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
It has been a better year for the Russell 2000 and the small-caps it represents.
New Year's Investing Resolutions
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Another Day of Rotation, but of a Different Sort
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Three Biotech Names to Consider
A look at three names to consider in the biotech and biopharma space.
Getting Ready for Biotech Earnings
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
7 Hot Investing Bets to Make in Biotech
These favorite names in the volatile sector offer the potential for high rewards.
Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
10 Biotech Stocks Investors Should Put on Their Shopping List for 2018
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
10 Biotech Stocks to Watch in 2018
There are a variety of players that should be active in the M&A space next year.
Alexion Suffers Quantitative Downgrade, Bearish Charts
The path of least resistance is downward for Alexion.
Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk
Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.
Now Up to the Plate, Today's Pinch Hitter, Bret Jensen!
It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...
Can Alexion Pharamaceuticals See an Upside Breakout?
A quantitative upgrade and chart patterns may do the trick.
Chipotle's Rally Could Resume
I am starting to watch a couple of key price zones on the way down.
Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
Small-Cap Action Is Improving
But I don't have a lot of confidence in this market beyond the intraday action.
Looking for the End of a Trend
Alexion Pharmaceuticals presents a tradeable countertrend opportunity.
The Good, the Bad and the Ugly (Another Boring Edition)
"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: " The Good, the Bad and the Ugly" https://www.youtube.com/watch? v=AFa1-kciCb4 No "Takeaways" today as the action was another painfully boring, uneventful and with litt...
Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low
If you want to stay active, you'll have to do more homework.
The Good, the Bad and the Ugly (Boring Edition)
"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, " The Good, the Bad and the Ugly" No "Takeaways" today as the action was kinda boring, uneventful and with little individual stock...
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Early-Morning Earnings Extravaganza
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Alexion's Billion Dollar Deal Is Largely Wasted
Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.
Bullish and Bearish Reversals in the Market
These companies show signs of a change of direction.